Development and Preclinical Evaluation of a Lyophilized Vaccine Against Equine Herpesvirus Type 4 (EHV-4)
Authors:
- Lespek KutumbetovLKLespek Kutumbetov
- Balzhan MyrzakhmetovaBMBalzhan Myrzakhmetova
- Aiganym TussipovaATAiganym Tussipova
- Gulzhan ZhapparovaGZGulzhan Zhapparova
- Talshyn TlenchiyevaTTTalshyn Tlenchiyeva
- Karina BissenbayevaKBKarina Bissenbayeva
- Sergazy NurabayevSNSergazy Nurabayev
- Aslan KerimbayevAKAslan Kerimbayev
Open Access
Abstract
Background/Objectives: Equine rhinopneumonia, caused by equine herpesvirus types 1 and 4 (EHV-1 and EHV-4), continues to be a significant health and economic concern in the global equine industry, particularly in Kazakhstan. While vaccines targeting EHV-1 are available, there is currently no licensed monovalent vaccine for EHV-4, and existing formulations offer limited protection against this serotype. This study aimed to develop and evaluate a freeze-dried, live-attenuated EHV-4 vaccine with improved safety, stability, and immunogenicity. Methods: A field isolate of EHV-4 was attenuated through serial passaging in primary lamb testicle (LT-KK49) cell cultures. Viral biomass was concentrated and formulated with various stabilizers before freeze-drying. The most effective stabilizer composition—sucrose, gelatin, and lactalbumin hydrolysate—was selected based on viral titer retention. Safety and immunogenicity were assessed in mice, guinea pigs, rabbits, donkeys, and horses. A guinea pig reproductive challenge model was used to evaluate protective efficacy. Results: The optimized lyophilized vaccine retained infectivity (>6.0 log10 TCID50/cm3) for at least six months at 4 °C. No adverse clinical signs were observed in any test species. Immunization induced robust neutralizing antibody responses in both small animals and equines. In the guinea pig model, vaccinated females demonstrated 100% pregnancy retention and fetal viability following challenge with a virulent EHV-4 strain. Conclusions: This freeze-dried, live-attenuated EHV-4 vaccine candidate is safe, immunogenic, and thermostable. It offers a promising platform for the targeted prevention of EHV-4 infection, particularly in young horses and in regions with limited cold-chain infrastructure.Keywords
Funding Information
- Ministry of Health of the Republic of Kazakhstan
This publication has 28 references indexed in Scilit:
- Vaccination for the prevention of equine herpesvirus-1 disease in domesticated horses: A systematic review and meta-analysisJournal of Veterinary Internal Medicine, 2024
- Equine herpesvirus 4 infected domestic horses associated with Sintashta spoke-wheeled chariots around 4,000 years agoVirus Evolution, 2024
- Efficacy of vaccination against equine herpesvirus type 1 (EHV‐1) infection: Systematic review and meta‐analysis of randomised controlled challenge trialsEquine Veterinary Journal, 2022
- Antiviral strategies targeting herpesvirusesJournal of Virus Eradication, 2021
- Concurrent vaccination against equine influenza and equine herpesvirus – a practical approachInfluenza and Other Respiratory Viruses, 2016
- Equine herpesviruses type 1 (EHV-1) and 4 (EHV-4)—Masters of co-evolution and a constant threat to equids and beyondVeterinary Microbiology, 2013
- Equine herpesvirus 4: Recent advances using BAC technologyVeterinary Microbiology, 2011
- Equine herpesviruses 1 (EHV-1) and 4 (EHV-4) – epidemiology, disease and immunoprophylaxis: A brief reviewThe Veterinary Journal, 2005
- Equine herpesvirus 1 and 4Veterinary Clinics of North America: Equine Practice, 2004
- Equine viral vaccines: the past, present and futureVeterinary Research, 2004